MARKET

SRRA

SRRA

SIERRA ONCOLOGY
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3110
-0.0131
-4.04%
After Hours: 0.3040 -0.007 -2.25% 16:24 10/11 EDT
OPEN
0.3300
PREV CLOSE
0.3241
HIGH
0.3390
LOW
0.3022
VOLUME
781.33K
TURNOVER
--
52 WEEK HIGH
2.010
52 WEEK LOW
0.2950
MARKET CAP
16.31M
P/E (TTM)
-0.4010
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SRRA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SRRA News

  • 28 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.2d ago
  • The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
  • Benzinga.4d ago
  • The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
  • Benzinga.10/04 11:32
  • The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines
  • Benzinga.10/01 12:10

More

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.89%

Hot Stocks

Name
Price
%Change

About SRRA

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
More

Webull offers Sierra Oncology Inc (SRRA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.